Unani Medicine, with its foundational concept of temperament (Mizaj), provides a unique and personalized framework for disease predisposition, prevention, and management. Recent advancements in genomics have opened new avenues to scientifically validate and deepen our understanding of temperament diversity. This review explores genome-wide analysis approaches applied to temperament classification in Unani Medicine, synthesizing evidence from contemporary genetic research and clinical observations. The article aims to integrate classical Unani perspectives with modern genetic insights, elucidate the pathophysiological basis of temperament, and discuss clinical implications, risk stratification, and personalized management strategies.
Unani Medicine, a system rooted in Greco-Arabic tradition, emphasizes the principle of individual temperament (Mizaj) as a central determinant of health and disease. Temperament is classified into four primary types—Damwi (sanguine), Balghami (phlegmatic), Safrawi (choleric), and Saudawi (melancholic)—each characterized by distinctive physiological and psychological traits. With the advent of genome-wide association studies (GWAS), there is growing interest in decoding the genetic basis of these temperament types to enhance the scientific validity and clinical utility of Unani diagnostics and therapeutics. This article critically reviews the intersection of Unani temperament theory and genomics, offering practice-oriented insights for clinicians and researchers.
Temperament diversity is universally recognized in Unani Medicine as a determinant of susceptibility to various diseases, influencing population health outcomes and disease distribution patterns. Epidemiological studies indicate that certain temperament types are overrepresented in specific geographic, ethnic, and familial cohorts, correlating with the prevalence of metabolic, cardiovascular, and neuropsychiatric disorders. Genome-wide analyses have further identified population-specific genetic markers associated with temperament, shedding light on hereditary disease risk and the burden of temperament-linked conditions in clinical practice.
Unani pathophysiology attributes temperament diversity to the quantitative and qualitative balance of four humours—blood, phlegm, yellow bile, and black bile. Modern research, leveraging GWAS and systems biology, suggests that genetic polymorphisms and epigenetic modifications underlie the neuroendocrine and immunological profiles that correspond with classical temperaments. For instance, variations in genes regulating serotonin, dopamine, and inflammatory cytokines have been associated with distinct temperament traits, bridging Unani concepts with molecular mechanisms of disease predisposition and resilience.
Both classical Unani doctrine and contemporary genetics recognize intrinsic and extrinsic factors influencing temperament formation. Genetic predisposition, environmental exposures, early-life nutrition, and psychosocial stressors contribute to temperament differentiation and its associated risk profiles. Genome-wide approaches have identified risk alleles and gene-environment interactions that modulate the development of temperament and its impact on chronic disease susceptibility, providing a foundation for risk stratification in preventive and personalized medicine.
Clinically, each Unani temperament exhibits a constellation of physical, psychological, and behavioral traits that predispose individuals to specific disease patterns. Damwi types may display robust cardiovascular health but are prone to inflammatory disorders, while Balghami individuals often present with metabolic sluggishness and increased risk of obesity or type 2 diabetes. Safrawi temperament is associated with hyperactivity and gastrointestinal complaints, whereas Saudawi types tend toward depressive symptoms and neurodegenerative risks. Recent genetic studies support these clinical observations, correlating temperament types with specific biomarkers and metabolic signatures.
Traditional Unani diagnosis of temperament integrates detailed history, physical examination, and qualitative assessment of humoral balance. Genome-wide analysis offers an objective, reproducible adjunct by identifying single nucleotide polymorphisms (SNPs) and gene expression profiles linked to temperament categories. Integrative diagnostic models combining classical assessment with molecular genotyping enhance diagnostic accuracy and enable early identification of at-risk individuals, facilitating tailored interventions.
Management in Unani Medicine is inherently personalized, with interventions—dietary, pharmacological, and lifestyle—tailored to the individual\'s temperament. Genome-wide findings now inform the selection of therapies by predicting treatment response and adverse event risk based on genetic background. For example, individuals with genetic variants predisposing to inflammation may benefit from anti-inflammatory diets and botanicals, while those with metabolic risk alleles can be guided toward specific lifestyle modifications. The integration of genomics enhances the precision of Unani therapeutic strategies and mitigates the risk of iatrogenic complications.
The application of GWAS and next-generation sequencing in Unani research has enabled the identification of temperament-associated genetic markers and pathways. Pharmacogenomics is emerging as a transformative discipline, allowing for the customization of Unani pharmacotherapy based on genetic makeup. Studies are underway to develop temperament-specific nutrigenomic protocols and gene-based screening tools, aiming to optimize preventive and therapeutic outcomes. These advances are paving the way for evidence-based, mechanism-driven Unani practice in the era of precision medicine.
Recent guidelines from integrative medicine societies advocate for the inclusion of genetic risk assessment in temperament evaluation. Clinicians are encouraged to combine traditional Unani assessment with molecular diagnostics to refine patient stratification, guide intervention selection, and monitor therapeutic efficacy. Multidisciplinary collaboration between Unani practitioners, geneticists, and clinical researchers is recommended to build robust, evidence-based protocols and enhance the translational impact of genomic discoveries in clinical practice.
The convergence of Unani temperament theory and genome-wide analysis represents a paradigm shift toward scientifically grounded, individualized medicine. Unraveling the genetic architecture of temperament not only validates classical Unani concepts but also empowers clinicians to implement precision diagnostics and targeted therapies. Ongoing research and interdisciplinary collaboration are essential to fully harness the clinical potential of genome-guided temperament assessment, transforming preventive, diagnostic, and therapeutic strategies in Unani and integrative medicine.
1.
Health of Myeloma Patient's Marriage Tied to Recovery After Transplant
2.
Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.
3.
Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC
4.
EBCC: European Breast Cancer Conference
5.
Charting the Course: From Young Adult Leukemia Patient to Oncologist.
1.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
2.
A New Perspective on Spherocytosis: Uncovering Innovative Treatments
3.
Pathophysiology of Tumor Cell Extracellular Matrix Remodeling
4.
Innovative Advances in Oncology for Specialists
5.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
2.
Importance of Cancer Screening and Early Detection
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation